Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CECIL M FARRINGTON

Allopathic & Osteopathic Physicians Family Medicine

NPI
1114913134
CMS profile
5527
Location
SALISBURY, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,638.81

135 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,638.81 135

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CECIL M FARRINGTON

NPI 1114913134 · CMS profile ID 5527

Allopathic & Osteopathic Physicians / Family Medicine

SALISBURY, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1114913134?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CECIL M FARRINGTON, NPI 1114913134, CMS profile ID 5527. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1114913134?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CECIL M FARRINGTON, NPI 1114913134, CMS profile ID 5527. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1114913134?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CECIL M FARRINGTON, NPI 1114913134, CMS profile ID 5527, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1114913134?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

135 matching records · $2,638.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 135 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–135 of 135.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $14.9904/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954877291 CMS
ABBVIE INC. $21.5704/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890944209 CMS
SANOFI-AVENTIS U.S. LLC $14.8404/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938766187 CMS
PFIZER INC. $18.3704/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949119603 CMS
Novo Nordisk Inc $7.9404/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899006263 CMS
ABBVIE INC. $14.6804/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890944207 CMS
AstraZeneca Pharmaceuticals LP $13.5404/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920225939 CMS
Janssen Pharmaceuticals, Inc $0.7604/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886581371 CMS
Janssen Pharmaceuticals, Inc $2.3404/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886581375 CMS
Amgen Inc. $18.6704/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939298293 CMS
Biohaven Pharmaceutical Holding Company Ltd. $13.7704/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923586633 CMS
Novo Nordisk Inc $59.3103/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899485677 CMS
Abbott Laboratories $18.2003/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920416335 CMS
Janssen Pharmaceuticals, Inc $5.2603/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886581381 CMS
ABBVIE INC. $13.5703/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890944205 CMS
AstraZeneca Pharmaceuticals LP $13.2203/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920233471 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.5403/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887589597 CMS
GlaxoSmithKline, LLC. $16.6103/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945179083 CMS
Lilly USA, LLC $24.1103/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917940111 CMS
Amgen Inc. $15.1203/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939298291 CMS
GlaxoSmithKline, LLC. $16.9903/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945179081 CMS
Janssen Pharmaceuticals, Inc $1.2702/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886581387 CMS
Novo Nordisk Inc $6.9202/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899418101 CMS
SANOFI-AVENTIS U.S. LLC $9.4402/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938766165 CMS
ABBVIE INC. $16.8002/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890944203 CMS
Janssen Pharmaceuticals, Inc $58.1402/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886581347 CMS
AstraZeneca Pharmaceuticals LP $15.2902/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920259463 CMS
Amgen Inc. $18.1402/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939298289 CMS
Novo Nordisk Inc $14.1802/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899006269 CMS
Lilly USA, LLC $12.9101/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917933743 CMS
SANOFI-AVENTIS U.S. LLC $63.6401/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938766159 CMS
PFIZER INC. $14.5101/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949059697 CMS
GlaxoSmithKline, LLC. $18.7301/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945179085 CMS
AstraZeneca Pharmaceuticals LP $54.8901/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920237413 CMS
ABBVIE INC. $4.9801/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890944201 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $937.74 17
PY2020 $1,474.43 14
PY2021 $989.26 22
PY2022 $2,638.81 135
PY2023 $163.57 3
PY2024 $15.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $566,684.52 30
PY2024 Recipient $1,787.95 14
PY2024 Principal investigator $711,595.62 38
PY2023 Principal investigator $978,116.92 83
PY2022 Principal investigator $1,160,449.26 85
PY2021 Principal investigator $1,179,893.75 96
PY2020 Principal investigator $1,580,621.45 117
PY2019 Principal investigator $167,554.32 67

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202534287
Principal investigator 1 ABBVIE INC. $44.80 12/31/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202535229
Principal investigator 1 ABBVIE INC. $23,377.40 12/31/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202535231
Principal investigator 1 ABBVIE INC. $23,377.40 12/31/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202535233
Principal investigator 1 ABBVIE INC. $23,377.40 12/31/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202535235
Principal investigator 1 Merck Sharp & Dohme LLC $31,605.34 12/31/2025 Non-covered Recipient Entity
PMG Research of Salisbury
A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent No dispute reported 06/30/2026 1232937540
Principal investigator 1 ABBVIE INC. $35,025.75 12/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529326
Principal investigator 1 ABBVIE INC. $1,440.00 11/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202525266
Principal investigator 1 ABBVIE INC. $67,456.80 11/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521955
Principal investigator 1 ABBVIE INC. $500.00 11/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202520433
Principal investigator 1 ABBVIE INC. $33,180.30 10/09/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202514245
Principal investigator 1 ABBVIE INC. $82.60 09/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202512250
Principal investigator 1 ABBVIE INC. $1,440.00 09/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202512392
Principal investigator 1 ABBVIE INC. $47,455.20 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202508780
Principal investigator 1 ABBVIE INC. $64,007.55 08/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503485
Principal investigator 1 GlaxoSmithKline, LLC. $1,999.00 08/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167569
Principal investigator 1 ABBVIE INC. $44.80 07/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202499612
Principal investigator 1 GlaxoSmithKline, LLC. $2,999.00 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167564
Principal investigator 1 ABBVIE INC. $52,802.55 07/02/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495643
Principal investigator 1 ABBVIE INC. $42,701.85 06/03/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202488239
Principal investigator 1 ABBVIE INC. $19,815.30 05/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483525
Principal investigator 1 ABBVIE INC. $18,293.85 04/03/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202469436
Principal investigator 1 ABBVIE INC. $4,726.64 03/17/2025 Non-covered Recipient Entity
ACCELLACARE US INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202463959
Principal investigator 1 ABBVIE INC. $500.00 03/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202462276
Principal investigator 1 ABBVIE INC. $4,726.64 03/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202462279
Principal investigator 1 ABBVIE INC. $33,380.10 03/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202459809
Principal investigator 1 ABBVIE INC. $24,472.80 02/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202447011
Principal investigator 1 Merck Sharp & Dohme LLC $714.60 01/27/2025 Non-covered Recipient Entity
PMG Research of Salisbury
A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent No dispute reported 06/30/2026 1232937538
Principal investigator 1 ABBVIE INC. $176.85 01/13/2025 Non-covered Recipient Entity
ACCELLACARE US INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202438080
Principal investigator 1 ABBVIE INC. $1,440.00 01/13/2025 Non-covered Recipient Entity
ACCELLACARE US INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202438083